Growth factors

Recombinant Cell Culture Supplements Receive a Boost from Stem Cell Research Ventures; Demand for Novel Vaccines to Act as a Growth Lever, Says PMR

Retrieved on: 
Friday, March 20, 2020

Recombinant Cell Culture Supplements Market: Key Takeaways

Key Points: 
  • Recombinant Cell Culture Supplements Market: Key Takeaways
    Clinical growth factors will hold more than half of the market share owing to their escalated use in clinical studies.
  • Recombinant Cell Culture Supplements Market: Key Growth Drivers
    Government-supported researches and clinical trials are boosting the adoption of recombinant cell culture supplements.
  • Recombinant Cell Culture Supplements Market: Key Restraints
    The shortage of skilled professionals in the R& D segment utilizing recombinant cell culture supplements is a major challenge before the market.
  • Lack of laboratory infrastructure to use recombinant cell culture supplements is hindering the smooth adoption of recombinant cell culture supplements in clinical studies.

Human Platelet Lysate Market Set for Healthy Growth Prospects; Clinical Application Account for 90% of Demand, Says Persistence Market Research

Retrieved on: 
Wednesday, March 11, 2020

Favorable government regulations and upsurge in R&D investments are also bolstering the market growth, according to a new Persistence Market Research (PMR) report.

Key Points: 
  • Favorable government regulations and upsurge in R&D investments are also bolstering the market growth, according to a new Persistence Market Research (PMR) report.
  • Heparin-free platelet lysates and human platelet lysates will remain the preferred types in market.
  • North America continues to lead the global human platelet lysate market, with concentration of established research institutes in the region.
  • Soaring bacterial and viral infection cases would enhance the scope of application for human platelet lysates, generating growth opportunities in market.

Seurat Therapeutics Announces Novel Mechanisms from Rat Migraine Model of Intranasal Insulin-like Growth Factor-1

Retrieved on: 
Monday, February 10, 2020

Seurat Therapeutics, Inc. (Seurat) announced today the publication of preclinical studies of its lead product candidate, intranasal insulin-like growth factor-1 (IGF-1), in a rat model of migraine headaches, in the scientific journal Brain Research.

Key Points: 
  • Seurat Therapeutics, Inc. (Seurat) announced today the publication of preclinical studies of its lead product candidate, intranasal insulin-like growth factor-1 (IGF-1), in a rat model of migraine headaches, in the scientific journal Brain Research.
  • Seurat is the world-wide licensee of patents for nasal IGF-1 treatment of migraine headaches from the University of Chicago.
  • The publication reports that trigeminal pain pathway activation is significantly reduced after intranasal IGF-1 treatment.
  • These findings support that intranasal IGF-1 has a unique potential to safely prevent migraine headaches through multiple novel mechanisms.

Granulocyte Macrophage Colony Stimulating Factor - Pipeline Review, H1 2020 - ResearchAndMarkets.com

Retrieved on: 
Friday, January 31, 2020

The "Granulocyte Macrophage Colony Stimulating Factor - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Granulocyte Macrophage Colony Stimulating Factor - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) pipeline Target constitutes close to 25 molecules.
  • The latest report Granulocyte Macrophage Colony Stimulating Factor - Pipeline Review, H1 2020, outlays comprehensive information on the Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a glycoprotein secreted by macrophages, T cells, mast cells, NK cells, endothelial cells and fibroblasts.

Granulocyte Macrophage Colony Stimulating Factor, Pipeline Review, H2 2019 - Amgen Inc, Seagull Labs Pvt Ltd & Cold Genesys Inc - ResearchAndMarkets.com

Retrieved on: 
Monday, January 20, 2020

The "Granulocyte Macrophage Colony Stimulating Factor - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Granulocyte Macrophage Colony Stimulating Factor - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • According to the recently published report 'Granulocyte Macrophage Colony Stimulating Factor - Pipeline Review, H2 2019'; Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) pipeline Target constitutes close to 25 molecules.
  • Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a glycoprotein secreted by macrophages, T cells, mast cells, NK cells, endothelial cells and fibroblasts.
  • The report 'Granulocyte Macrophage Colony Stimulating Factor - Pipeline Review, H2 2019' outlays comprehensive information on the Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

Generex Biotechnology Subsidiary Olaregen Therapeutix Announces the Introduction of Excellagen Aesthetics™

Retrieved on: 
Friday, January 17, 2020

MIRAMAR, Fla., Jan. 17, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation ( www.generex.com ) ( GNBT ) ( http://www.otcmarkets.com/stock/GNBT/quote ) is pleased to announce that their subsidiary, Olaregen Therapeutix, Inc., is introducing an exciting new product, Excellagen Aesthetics for the cosmetic surgery and aesthetic dermatology market.

Key Points: 
  • MIRAMAR, Fla., Jan. 17, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation ( www.generex.com ) ( GNBT ) ( http://www.otcmarkets.com/stock/GNBT/quote ) is pleased to announce that their subsidiary, Olaregen Therapeutix, Inc., is introducing an exciting new product, Excellagen Aesthetics for the cosmetic surgery and aesthetic dermatology market.
  • Excellagen Aesthetics has been shown in vitro to trigger the localized release of endogenous growth factors including Platelet-Derived Growth Factor (PDGF), a key biological mediator of wound healing.
  • Olaregen is rolling out Excellagen Aesthetics with a dedicated contract sales force uniquely positioned in major metropolitan areas across the United States where the majority of aesthetic dermatology procedures are clustered.
  • Olaregen's first product introduction, Excellagen (flowable dermal matrix) is a topically applied product for dermal wounds and other indications.

Growth Differentiation Factor 8, Pipeline Review, H2 2019 - Biogen Inc, PeptiDream Inc, Pfizer & Regeneron Pharmaceuticals Inc - ResearchAndMarkets.com

Retrieved on: 
Friday, January 17, 2020

The "Growth Differentiation Factor 8 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Growth Differentiation Factor 8 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • According to the recently published report 'Growth Differentiation Factor 8 - Pipeline Review, H2 2019'; Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) pipeline Target constitutes close to 10 molecules.
  • Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Myostatin also known as growth differentiation factor 8 or GDF-8 is a myokine a protein produced and released by myocytes.
  • This protein is part of the transforming growth factor beta (TGF) superfamily.

2019 Insulin Like Growth Factor II - Pipeline Review & Analysis, H2 - ResearchAndMarkets.com

Retrieved on: 
Friday, January 3, 2020

The "Insulin Like Growth Factor II - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Insulin Like Growth Factor II - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) pipeline Target constitutes close to 7 molecules.
  • The latest report Insulin Like Growth Factor II - Pipeline Review, H2 2019, outlays comprehensive information on the Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • It also reviews key players involved in Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) targeted therapeutics development with respective active and dormant or discontinued projects.

Savara Granted Breakthrough Therapy Designation for Molgradex for the Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Retrieved on: 
Monday, December 30, 2019

Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of aPAP.

Key Points: 
  • Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of aPAP.
  • The Molgradex Breakthrough Therapy designation is based on data from IMPALA, a pivotal Phase 3 clinical study evaluating Molgradex for the treatment of aPAP.
  • We are pleased that the FDA recognized Molgradex as a breakthrough therapy for the treatment of aPAP, a debilitating rare lung disease with no approved pharmacologic treatment options, said Rob Neville, Chief Executive Officer, Savara.
  • We believe this designation reflects the significance of Molgradex as an investigational product that, based on the IMPALA study, has been demonstrated to improve patient outcomes.

Fibroblast Growth Factor 2 - Pipeline Review, H2 2019 - ResearchAndMarkets.com

Retrieved on: 
Monday, December 30, 2019

The "Fibroblast Growth Factor 2 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Fibroblast Growth Factor 2 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • According to the recently published report 'Fibroblast Growth Factor 2 - Pipeline Review, H2 2019'; Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) pipeline Target constitutes close to 10 molecules.
  • Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Basic fibroblast growth factor also known as bFGF or FGF2 is a member of the fibroblast growth factor family.
  • This protein plays an important role in diverse biological processes, such as limb and nervous system development, wound healing, and tumor growth.